This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Macular Disorders  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic

Mandar M. Joshi, MD; Bruce R. Garretson, MD

Arch Ophthalmol. 2007;125(5):709-710.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Cystoid macular edema (CME) is thought to result from disruption of the normal blood-retinal barrier. Leakage from parafoveal capillaries is demonstrated on fluorescein angiograms in a classic petalloid pattern in typical CME.¹

Expansion of the intracellular fluid space may also lead to CME. Accumulation of fluid in the intracellular space may lead to CME without evidence of leakage on fluorescein angiograms.² We report a case in which CME was secondary to paclitaxel (Taxol; Bristol-Meyers Squibb Co, New York, NY) use without evidence of leakage at angiography.

Report of a Case

A 63-year-old woman reported gradual decreased vision in both eyes. The patient's medical history was significant for metastatic breast carcinoma with previous radiation therapy to the brain. Her chemotherapeutic regimen consisted of trastuzumab (Herceptin; Genentech Inc, South San Francisco, Calif) and paclitaxel (175 mg/m² for 10 months). At the initial ophthalmologic examination, the best-corrected visual acuity . . . [Full Text of this Article]

Comment

AUTHOR INFORMATION